A new AI-derived tumor marker can enhance treatment response assessment in pancreatic cancer patients who do not produce elevated CA19-9.

• In a study of 121 patients, a 50% or more decline in the marker (e19-9) was linked to a 5-fold higher likelihood of completing neoadjuvant therapy and surgery.
• An e19-9 level below 100 significantly correlated with improved overall survival (hazard ratio 0.49).

Consider integrating e19-9 monitoring into clinical practice for nonproducing CA19-9 patients to optimize treatment planning and prognostication.